TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small... TTP889 has proven to be effective in preventing clot formation in several animal models of human disease, without any signs of the bleeding associated with traditional anticoagulants.
- Mechanism
- Curator reviewed
TTP889 is a factor IXa inhibitor with little or no activity against factors VIIIa, Xa, XIa, or XIIa. It is the only molecule in development that is an inhibitor of the intrinsic pathway in vitro and in vivo via FIX/IXa. TTP889 inhibits the ability of FIXa to form a fully functional tenase complex with FVIIIa. FIXa plays an integral role in the intrinsic coagulation pathway and a lesser role in the extrinsic pathway.
- Primary indication
- Investigated for use/treatment in blood (blood forming organ disorders, unspecified), cardiac surgery, and venous thromboembolism.Curator reviewed
- Code names
- TTP889
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with TTP889, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account